FIL Ltd Reduces Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

FIL Ltd cut its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 6.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,943,061 shares of the company's stock after selling 130,764 shares during the period. FIL Ltd owned approximately 1.57% of Guardant Health worth $59,361,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in GH. Norges Bank bought a new position in Guardant Health during the 4th quarter valued at about $36,438,000. Lord Abbett & CO. LLC bought a new position in Guardant Health during the third quarter valued at approximately $15,624,000. Vanguard Group Inc. boosted its holdings in Guardant Health by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock worth $368,205,000 after purchasing an additional 350,606 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in Guardant Health by 19.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after purchasing an additional 238,037 shares during the period. Finally, Prudential Financial Inc. raised its stake in Guardant Health by 2,235.6% during the 4th quarter. Prudential Financial Inc. now owns 229,870 shares of the company's stock valued at $7,023,000 after buying an additional 220,028 shares during the last quarter. Institutional investors own 92.60% of the company's stock.

Guardant Health Trading Up 0.6 %

GH traded up $0.28 during trading on Tuesday, hitting $45.44. 667,722 shares of the company traded hands, compared to its average volume of 2,303,875. The company has a market cap of $5.61 billion, a PE ratio of -12.76 and a beta of 1.45. The stock's 50-day simple moving average is $43.53 and its two-hundred day simple moving average is $35.93. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $50.89.

Remove Ads

Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Equities analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on GH shares. Guggenheim reaffirmed a "buy" rating and issued a $56.00 price objective on shares of Guardant Health in a report on Monday, February 24th. Mizuho assumed coverage on shares of Guardant Health in a research report on Thursday, April 10th. They set an "outperform" rating and a $55.00 price target for the company. Morgan Stanley raised their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a report on Thursday, March 6th. Canaccord Genuity Group boosted their target price on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, February 24th. Finally, Stephens reiterated an "overweight" rating and set a $55.00 price target on shares of Guardant Health in a research note on Wednesday, March 26th. Twenty research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Guardant Health currently has an average rating of "Buy" and a consensus price target of $49.00.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.